The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) is a huge mover today! About 213,498 shares traded hands or 105.84% up from the average. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 58.93% since April 5, 2016 and is downtrending. It has underperformed by 60.88% the S&P500.
The move comes after 5 months positive chart setup for the $31.81M company. It was reported on Nov, 8 by Barchart.com. We have $4.67 PT which if reached, will make NASDAQ:OREX worth $33.08M more.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Ratings Coverage
Out of 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 40% are positive. Orexigen Therapeutics has been the topic of 12 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock has “Underperform” rating given by Bank of America on Friday, December 11. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. RBC Capital Markets maintained the shares of OREX in a report on Friday, November 6 with “Outperform” rating. The firm has “Market Perform” rating given on Wednesday, March 16 by JMP Securities. As per Wednesday, August 5, the company rating was upgraded by Zacks. JP Morgan maintained it with “Buy” rating and $8 target price in Monday, August 10 report. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, October 6. The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) earned “Buy” rating by Piper Jaffray on Saturday, August 8. RBC Capital Markets upgraded the shares of OREX in a report on Tuesday, September 15 to “” rating.
According to Zacks Investment Research, “OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company’s lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company’s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.”
Insitutional Activity: The institutional sentiment decreased to 0.27 in 2016 Q2. Its down 0.46, from 0.73 in 2016Q1. The ratio dropped, as 42 funds sold all Orexigen Therapeutics, Inc. shares owned while 28 reduced positions. 9 funds bought stakes while 10 increased positions. They now own 61.80 million shares or 34.69% less from 94.63 million shares in 2016Q1.
California Public Employees Retirement Systems holds 335,200 shares or 0% of its portfolio. Jpmorgan Chase And holds 1,000 shares or 0% of its portfolio. The California-based Bvf Incorporated Il has invested 0.48% in Orexigen Therapeutics, Inc. (NASDAQ:OREX). Foresite Cap Mngmt Ii Limited Liability Corp last reported 5.43M shares in the company. Ladenburg Thalmann Financial Services reported 850 shares or 0% of all its holdings. Stifel reported 30,100 shares or 0% of all its holdings. Citigroup Inc last reported 0% of its portfolio in the stock. Huntington Natl Bank last reported 3,689 shares in the company. Cqs Cayman Lp accumulated 0% or 113,000 shares. Great West Life Assurance Can last reported 15,717 shares in the company. Blackrock Fund Advsrs owns 1.96 million shares or 0% of their US portfolio. Retail Bank Of America Corporation De accumulated 240,880 shares or 0% of the stock. Ameriprise Financial Inc accumulated 0% or 13,270 shares. Rock Springs Capital Mgmt Limited Partnership accumulated 0.05% or 1.65M shares. Pnc Finance Svcs Inc has 859 shares for 0% of their US portfolio.
More important recent Orexigen Therapeutics, Inc. (NASDAQ:OREX) news were published by: Prnewswire.com which released: “Orexigen Therapeutics Announces Commercialization and Distributorship …” on November 08, 2016, also Fool.com published article titled: “Blame This for Orexigen Therapeutics, Inc.’s Mind-Numbingly Bad 2015”, Prnewswire.com published: “Orexigen Therapeutics Announces Commercialization and Distributorship …” on August 01, 2016. More interesting news about Orexigen Therapeutics, Inc. (NASDAQ:OREX) was released by: Prnewswire.com and their article: “Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth …” with publication date: April 25, 2016.
OREX Company Profile
Orexigen Therapeutics, Inc., incorporated on September 12, 2002, is a biopharmaceutical company. The Firm is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.